Strain Name:

STOCK Pitx3ak/2J

Stock Number:

000942

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Other products are available, see Purchasing Information for Cryopreserved Embryos

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6 x C57BLKS-Pitx3ak/J    (Changed: 04-MAY-05 )
Type Mutant Strain; Spontaneous Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
GenerationN6p
Generation Definitions

Description
Mice homozygous for the Pitx3ak mutation exhibit microphthalmia (small eyes) and aphakia (no lens) related to arrested lens development. The mesencephalic dopamine system is malformed and as a result homozygotes fail to develop dopaminergic neurons of the substantia nigra (Smidt et al., 2004). Homozygotes display sensorimotor deficits specific to the nigrostriatal pathway such as the challenge beam and pole test and the test for spontaneous exploratory activitiy in a cylinder. These deficits can be reversed by L-DOPA administration (Hwang et al., 2005). This mutant mouse strain may be useful in studies of Parkinson's disease.

Development
The aphakia allele arose spontaneously in 1981 on the 129S1/Sv-p+ Tyr+ KitlSl-J/J strain. A female with a small right eye was mated to a male with small left eye (male 1). The mating produced greater than 50% bilaterally aphakic pups. As a result of poor breeding on the original129S1 background, male 1 was mated to a C57BLKS/J female. The one F1 aphakic female produced was used to build the colony. The colony was maintained by occasional crossing to C57BLKS/J (Varnum et al. 1968). This strain was cryopreserved in 1984 using homozygous males at generation N5F39 or N5F40 bred to C57BL/6J females. The strain was cryo-recovered in 2005.

Control Information

  Control
   Heterozygote from the colony
 
  Considerations for Choosing Controls

Related Strains

Parkinson's Disease Models
005987   129-Achetm1Loc/J
007587   129S-Park2tm1Rpa/J
002779   129S-Parp1tm1Zqw/J
017001   129S.B6N-Plk2tm1Elan/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
004608   B6(Cg)-Htra2mnd2/J
021828   B6(SJL)-Lrrk2tm3.1Mjff/J
008133   B6.129-Sncbtm1Sud/J
008084   B6.129P2-Drd4tm1Dkg/J
004744   B6.129P2-Esr1tm1Ksk/J
013586   B6.129P2-Gt(ROSA)26Sortm1Nik/J
002609   B6.129P2-Nos2tm1Lau/J
008843   B6.129P2-Sncgtm1Vlb/J
016566   B6.129S-Hcn1tm2Kndl/J
004322   B6.129S1-Mapk10tm1Flv/J
003190   B6.129S2-Drd2tm1Low/J
006582   B6.129S4-Park2tm1Shn/J
017946   B6.129S4-Pink1tm1Shn/J
005934   B6.129S4-Ucp2tm1Lowl/J
004936   B6.129S6(Cg)-Spp1tm1Blh/J
012453   B6.129X1(FVB)-Lrrk2tm1.1Cai/J
017009   B6.129X1-Nfe2l2tm1Ywk/J
009346   B6.Cg-Lrrk2tm1.1Shn/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
006577   B6.Cg-Park7tm1Shn/J
000567   B6.Cg-T2J +/+ Qkqk-v/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
003139   B6.Cg-Tg(DBHn-lacZ)8Rpk/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
012466   B6.Cg-Tg(Lrrk2)6Yue/J
012467   B6.Cg-Tg(Lrrk2*G2019S)2Yue/J
008323   B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J
008321   B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J
008324   B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J
008322   B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J
007894   B6.Cg-Tg(Rgs4-EGFP)4Lvt/J
012588   B6.Cg-Tg(TH-ALPP)1Erav/J
012265   B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J
008859   B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J
008135   B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J
008601   B6.Cg-Tg(Th-cre)1Tmd/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
000544   B6.D2-Cacna1atg/J
012445   B6.FVB-Tg(LRRK2)WT1Mjfa/J
012446   B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J
006660   B6.SJL-Slc6a3tm1.1(cre)Bkmn/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
009688   B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J
008883   B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ
008889   B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ
008886   B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ
009347   B6;129-Lrrk2tm1.1Shn/J
016209   B6;129-Lrrk2tm2.1Shn/J
016210   B6;129-Lrrk2tm3.1Shn/J
013050   B6;129-Pink1tm1Aub/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
006390   B6;129-Sncatm1Sud Sncbtm1.1Sud/J
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008333   B6;129P2-Dldtm1Ptl/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003243   B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J
003692   B6;129X1-Sncatm1Rosl/J
016575   B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J
016576   B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
000231   B6;C3Fe a/a-Csf1op/J
012450   B6;D2-Tg(tetO-SNCA)1Cai/J
013725   B6;SJL-Tg(LRRK2)66Mjff/J
008473   B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J
008134   B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
000506   B6C3Fe a/a-Qkqk-v/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
024841   B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J
018768   B6N.Cg-Tg(SNCA*E46K)3Elan/J
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
016120   C57BL/6-Lrrk1tm1.1Mjff/J
012444   C57BL/6-Lrrk2tm1Mjfa/J
008389   C57BL/6-Tg(THY1-SNCA)1Sud/J
012769   C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
018785   C57BL/6J-Tg(LRRK2*G2019S)2AMjff/J
018786   C57BL/6J-Tg(LRRK2*R1441G)3IMjff/J
008245   C57BL/6J-Tg(Th-SNCA)5Eric/J
008239   C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J
016122   C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J
016121   C57BL/6N-Lrrk2tm1.1Mjff/J
016123   C57BL/6N-Sncatm1Mjff/J
016936   C57BL/6N-Tg(Thy1-SNCA)12Mjff/J
017682   C57BL/6N-Tg(Thy1-SNCA)15Mjff/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
009610   FVB/N-Tg(LRRK2)1Cjli/J
009609   FVB/N-Tg(LRRK2*G2019S)1Cjli/J
009604   FVB/N-Tg(LRRK2*R1441G)135Cjli/J
009090   FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J
017678   FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J
017744   FVB;129-Tg(Prnp-SNCA*A53T)AAub/J
010710   FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J
010788   FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J
010799   FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
006340   STOCK Tg(Gad1-EGFP)98Agmo/J
017000   STOCK Tg(SNCA*E46K)3Elan/J
008474   STOCK Tg(THY1-SNCA*A53T)F53Sud/J
008132   STOCK Tg(THY1-Snca)M1mSud/J
012441   STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J
012442   STOCK Tg(tetO-SNCA*A53T)E2Cai/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Parkinson's Disease Models     (112 strains)

Strains carrying other alleles of Pitx3
022306   B6N(Cg)-Pitx3tm1.1(KOMP)Vlcg/J
View Strains carrying other alleles of Pitx3     (1 strain)

Additional Web Information

Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Anterior Segment Mesenchymal Dysgenesis; ASMD
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Cataract 11, Multiple Types; CTRCT11   (PITX3)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Pitx3ak/Pitx3ak

        involves: 129S1/Sv * C57BL/6 * C57BLKS/J
  • nervous system phenotype
  • abnormal dorsal striatum morphology
    • results using the key dopamine neuronal marker, TH, suggest a reduction of neurons in the dorsal striatum, however, not in the nucleus accumbens or olfactory tubercle implying a defective nigrostriatal pathway   (MGI Ref ID J:109319)
  • abnormal substantia nigra morphology
    • Nissl staining indicates that cell density is dramatically reduced in the substantia nigra pas as compared to wild-type   (MGI Ref ID J:109319)
    • dopaminergic neurons remaining in the substantia nigra appear atrophic with somewhat shrunken cell bodies   (MGI Ref ID J:109319)
    • results using both the key dopamine neuronal marker, TH, and Fluorogold retrograde labeling suggest the absence of dopaminergic neurons in the substantia nigra pas compacta indicating that nigrostriatal projections do not develop   (MGI Ref ID J:109319)
    • neuron loss is apparent in newborn mice   (MGI Ref ID J:109319)
  • decreased dopamine level
    • levels are reduced to 10% of wildtype in the dorsal striatum, however levels in the ventral striatum are not affected   (MGI Ref ID J:109319)
  • loss of dopaminergic neurons
    • selective loss of A9 dopaminergic neurons in the substantia nigra; A10 neurons in the ventral tegmental area appear to be intact   (MGI Ref ID J:109319)
  • behavior/neurological phenotype
  • abnormal locomotor behavior
    • higher ambulatory activity than control during lights-on period, however, lower ambulatory activity than control during lights-off period   (MGI Ref ID J:98209)
    • decreased vertical activity
      • mice exhibit a decrease in rearing and hindlimb stepping as measured in the transparent cylinder, however, administration of L-DOPA increases spontaneous activity to the same or higher than wildtype   (MGI Ref ID J:98209)
    • hyperactivity
      • total horizontal movements during a 22 hour period are slightly increased over that of control   (MGI Ref ID J:98209)
  • impaired coordination
    • mice exhibit longer times to traverse a balance beam challenge and a 25% increase in the number of steps as compared to controls, however, administration of L-DOPA reduced beam time and step number almost to wild-type levels   (MGI Ref ID J:98209)
    • in a vertical pole test, mice take longer than controls to orient downwards; L-DOPA administration reduces orientation time   (MGI Ref ID J:98209)
  • homeostasis/metabolism phenotype
  • decreased dopamine level
    • levels are reduced to 10% of wildtype in the dorsal striatum, however levels in the ventral striatum are not affected   (MGI Ref ID J:109319)

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

Pitx3ak/Pitx3ak

        either: (involves: 129/Sv * C57BLKS) or (involves: 129/Sv * C57BL/6)
  • pigmentation phenotype
  • abnormal iris pigmentation
    • intensly pigmented around the pupil at E13   (MGI Ref ID J:5084)
    • pupillary area replaced by iris at E17-18   (MGI Ref ID J:5084)
  • behavior/neurological phenotype
  • hypoactivity
    • reduced spontaneous activity at night   (MGI Ref ID J:82907)
  • endocrine/exocrine gland phenotype
  • abnormal lacrimal gland morphology
    • enlarged lacrimal gland partially fills the orbit   (MGI Ref ID J:5084)
  • growth/size/body phenotype
  • decreased body size
    • slightly smaller than normal   (MGI Ref ID J:5084)
  • reproductive system phenotype
  • reduced fertility
    • fertility is reduced at generation F3 and beyond, particularly for females   (MGI Ref ID J:5084)
  • vision/eye phenotype
  • abnormal anterior eye segment morphology   (MGI Ref ID J:5084)
    • abnormal iris pigmentation
      • intensly pigmented around the pupil at E13   (MGI Ref ID J:5084)
      • pupillary area replaced by iris at E17-18   (MGI Ref ID J:5084)
    • abnormal lens development
      • little growth or organization of the lens vesicle after E11   (MGI Ref ID J:5084)
    • acoria
      • no pupil at birth   (MGI Ref ID J:5084)
  • abnormal eye distance/ position
    • ocular area slightly concave after eyes open   (MGI Ref ID J:5084)
  • abnormal lacrimal gland morphology
    • enlarged lacrimal gland partially fills the orbit   (MGI Ref ID J:5084)
  • abnormal posterior eye segment morphology   (MGI Ref ID J:5084)
    • abnormal ocular fundus morphology
      • abnormal growth of the eyecup after E13   (MGI Ref ID J:5084)
      • sensory and pigmented layers remain separated   (MGI Ref ID J:5084)
      • abnormal retina morphology
        • many retinal folds at birth   (MGI Ref ID J:5084)
        • partially fills the vitreous chamber   (MGI Ref ID J:5084)
  • microphthalmia
    • eyes slightly smaller than normal at birth   (MGI Ref ID J:5084)
    • slightly smaller and uneven at E13   (MGI Ref ID J:5084)
  • nervous system phenotype
  • abnormal midbrain morphology   (MGI Ref ID J:82746)
    • at E12.5, mesencephalon dopaminergic neurons are normal   (MGI Ref ID J:82907)
    • by the first day after birth there is a 91% reduction in neurons with tyrosine hydroxylase immunoreactivity   (MGI Ref ID J:82907)
    • reduced activity in the ventral tegmental area but slower to develop   (MGI Ref ID J:82907)
    • dorsal tier of the pars compacta of the substantia nigra retains tyrosine hydroxylase activity   (MGI Ref ID J:82907)
    • abnormal substantia nigra morphology
      • less cellularity in the substantia nigra   (MGI Ref ID J:82746)
      • tyrosine hydroxylase immunoreactivity absent in the substantia nigra   (MGI Ref ID J:82746)
      • decreased numbers of nigrostriatal fibers   (MGI Ref ID J:82746)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Pitx3ak related

Neurobiology Research
Parkinson's Disease

Sensorineural Research
Cataracts
      cortical

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Pitx3ak
Allele Name aphakia
Allele Type Spontaneous
Common Name(s) ak;
Strain of Origin129S1/Sv-Kitl
Gene Symbol and Name Pitx3, paired-like homeodomain transcription factor 3
Chromosome 19
Gene Common Name(s) ASMD; CTPP4; CTRCT11; PTX3; ak; aphakia;
General Note Phenotypic Similarity to Human Syndrome: Parkinson Disease (J:98209, J:104915)
Molecular Note This allele carries a 652 bp deletion in the promoter region of the gene, located 2.5 kb upstream of the transcription start site. The deletion cosegregated with the aphakia phenotype. In situ hybridization studies of homozygous mutant mice did not detect transcripts in the lens placode or at later developmental stages of the lens. [MGI Ref ID J:63167] [MGI Ref ID J:68175]

Genotyping

Genotyping Information


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Varnum DS; Stevens LC. 1968. Aphakia, a new mutation in the mouse. J Hered 59(2):147-50. [PubMed: 4970465]  [MGI Ref ID J:5084]

Additional References

Smidt MP; Smits SM; Bouwmeester H; Hamers FP; van der Linden AJ; Hellemons AJ; Graw J; Burbach JP. 2004. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131(5):1145-55. [PubMed: 14973278]  [MGI Ref ID J:88592]

Pitx3ak related

Ardayfio P; Moon J; Leung KK; Youn-Hwang D; Kim KS. 2008. Impaired learning and memory in Pitx3 deficient aphakia mice: A genetic model for striatum-dependent cognitive symptoms in Parkinson's disease. Neurobiol Dis :. [PubMed: 18573342]  [MGI Ref ID J:136304]

Ardayfio PA; Leung A; Park J; Hwang DY; Moran-Gates T; Choi YK; Carlezon WA Jr; Tarazi FI; Kim KS. 2010. Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs. Neuroscience 166(2):391-6. [PubMed: 20026251]  [MGI Ref ID J:159741]

Coulon V; L'Honore A; Ouimette JF; Dumontier E; van den Munckhof P; Drouin J. 2007. A muscle-specific promoter directs Pitx3 gene expression in skeletal muscle cells. J Biol Chem 282(45):33192-200. [PubMed: 17848564]  [MGI Ref ID J:126948]

Ding Y; Restrepo J; Won L; Hwang DY; Kim KS; Kang UJ. 2007. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 27(1):11-23. [PubMed: 17499513]  [MGI Ref ID J:122000]

Ding Y; Won L; Britt JP; Lim SA; McGehee DS; Kang UJ. 2011. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 108(2):840-5. [PubMed: 21187382]  [MGI Ref ID J:170567]

Espadas I; Darmopil S; Vergano-Vera E; Ortiz O; Oliva I; Vicario-Abejon C; Martin ED; Moratalla R. 2012. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis 48(3):271-81. [PubMed: 22820144]  [MGI Ref ID J:197507]

Grimm C; Chatterjee B; Favor J; Immervoll T; Loster J; Klopp N; Sandulache R; Graw J. 1998. Aphakia (ak), a mouse mutation affecting early eye development: fine mapping, consideration of candidate genes and altered Pax6 and Six3 gene expression pattern. Dev Genet 23(4):299-316. [PubMed: 9883582]  [MGI Ref ID J:51693]

Hwang DY; Ardayfio P; Kang UJ; Semina EV; Kim KS. 2003. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 114(2):123-31. [PubMed: 12829322]  [MGI Ref ID J:109319]

Hwang DY; Fleming SM; Ardayfio P; Moran-Gates T; Kim H; Tarazi FI; Chesselet MF; Kim KS. 2005. 3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci 25(8):2132-7. [PubMed: 15728853]  [MGI Ref ID J:98209]

Hwang DY; Hong S; Jeong JW; Choi S; Kim H; Kim J; Kim KS. 2009. Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J Neurochem 111(5):1202-12. [PubMed: 19780901]  [MGI Ref ID J:155057]

Jacobs FM; Smits SM; Noorlander CW; von Oerthel L; van der Linden AJ; Burbach JP; Smidt MP. 2007. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development 134(14):2673-84. [PubMed: 17592014]  [MGI Ref ID J:122792]

Jacobs FM; Veenvliet JV; Almirza WH; Hoekstra EJ; von Oerthel L; van der Linden AJ; Neijts R; Koerkamp MG; van Leenen D; Holstege FC; Burbach JP; Smidt MP. 2011. Retinoic acid-dependent and -independent gene-regulatory pathways of Pitx3 in meso-diencephalic dopaminergic neurons. Development 138(23):5213-22. [PubMed: 22069189]  [MGI Ref ID J:178682]

Kas MJ; van der Linden AJ; Oppelaar H; von Oerthel L; Ramakers GM; Smidt MP. 2008. Phenotypic segregation of aphakia and Pitx3-null mutants reveals that Pitx3 deficiency increases consolidation of specific movement components Behav Brain Res 186(2):208-14. [PubMed: 17919745]  [MGI Ref ID J:125552]

Kim J; Inoue K; Ishii J; Vanti WB; Voronov SV; Murchison E; Hannon G; Abeliovich A. 2007. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317(5842):1220-4. [PubMed: 17761882]  [MGI Ref ID J:125222]

Lennington JB; Pope S; Goodheart AE; Drozdowicz L; Daniels SB; Salamone JD; Conover JC. 2011. Midbrain dopamine neurons associated with reward processing innervate the neurogenic subventricular zone. J Neurosci 31(37):13078-87. [PubMed: 21917791]  [MGI Ref ID J:177043]

Li L; Qiu G; Ding S; Zhou FM. 2013. Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice. Brain Res 1491:236-50. [PubMed: 23159831]  [MGI Ref ID J:206553]

Li L; Zhou FM. 2013. Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice. Neuroscience 236:66-76. [PubMed: 23357114]  [MGI Ref ID J:201378]

Luk KC; Rymar VV; van den Munckhof P; Nicolau S; Steriade C; Bifsha P; Drouin J; Sadikot AF. 2013. The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. J Neurochem 125(6):932-43. [PubMed: 23331067]  [MGI Ref ID J:197868]

Medina-Martinez O; Shah R; Jamrich M. 2009. Pitx3 controls multiple aspects of lens development. Dev Dyn 238(9):2193-2201. [PubMed: 19334279]  [MGI Ref ID J:151273]

Nunes I; Tovmasian LT; Silva RM; Burke RE; Goff SP. 2003. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A 100(7):4245-50. [PubMed: 12655058]  [MGI Ref ID J:82746]

Papanikolaou T; Amano T; Lennington J; Sink K; Farrar AM; Salamone J; Yang X; Conover JC. 2009. In-vitro analysis of Pitx3 in mesodiencephalic dopaminergic neuron maturation. Eur J Neurosci 29(12):2264-75. [PubMed: 19508691]  [MGI Ref ID J:151532]

Rieger DK; Reichenberger E; McLean W; Sidow A; Olsen BR. 2001. A double-deletion mutation in the pitx3 gene causes arrested lens development in aphakia mice. Genomics 72(1):61-72. [PubMed: 11247667]  [MGI Ref ID J:68175]

Rosemann M; Ivashkevich A; Favor J; Dalke C; Holter SM; Becker L; Racz I; Bolle I; Klempt M; Rathkolb B; Kalaydjiev S; Adler T; Aguilar A; Hans W; Horsch M; Rozman J; Calzada-Wack J; Kunder S; Naton B; Gailus-Durner V; Fuchs H; Schulz H; Beckers J; BuschDH; Burbach JP; Smidt MP; Quintanilla-Martinez L; Esposito I; Klopstock T; Klingenspor M; Ollert M; Wolf E; Wurst W; Zimmer A; Hrabe de Angelis M; Atkinson M; Heinzmann U; Graw J. 2010. Microphthalmia, parkinsonism, and enhanced nociception in Pitx3 ( 416insG ) mice. Mamm Genome 21(1-2):13-27. [PubMed: 20033184]  [MGI Ref ID J:156878]

Semina EV; Murray JC; Reiter R; Hrstka RF; Graw J. 2000. Deletion in the promoter region and altered expression of pitx3 homeobox gene in aphakia mice Hum Mol Genet 9(11):1575-85. [PubMed: 10861284]  [MGI Ref ID J:63167]

Singh B; Wilson JH; Vasavada HH; Guo Z; Allore HG; Zeiss CJ. 2007. Motor deficits and altered striatal gene expression in aphakia (ak) mice. Brain Res 1185:283-92. [PubMed: 17949697]  [MGI Ref ID J:128707]

Smidt MP; Smits SM; Bouwmeester H; Hamers FP; van der Linden AJ; Hellemons AJ; Graw J; Burbach JP. 2004. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131(5):1145-55. [PubMed: 14973278]  [MGI Ref ID J:88592]

Smits SM; Mathon DS; Burbach JP; Ramakers GM; Smidt MP. 2005. Molecular and cellular alterations in the Pitx3-deficient midbrain dopaminergic system. Mol Cell Neurosci 30(3):352-63. [PubMed: 16140547]  [MGI Ref ID J:102233]

Smits SM; van der Nobelen S; Hornman KJ; von Oerthel L; Burbach JP; Smidt MP. 2005. Signalling through phospholipase C beta 4 is not essential for midbrain dopaminergic neuron survival. Neuroscience 136(1):171-9. [PubMed: 16198487]  [MGI Ref ID J:104551]

Varnum DS; Stevens LC. 1975. Aphakia linked with brachymorphic. Mouse News Lett 53:35.  [MGI Ref ID J:13685]

Webster EH Jr; Zwaan J; Cooper P. 1986. Abnormal accumulation of sulphated materials in lens tissue of mice with the aphakia mutation. J Embryol Exp Morphol 92:85-101. [PubMed: 3522797]  [MGI Ref ID J:8330]

Zwaan J. 1975. Immunofluorescent studies on aphakia, a mutation of a gene involved in the control of lens differentiation in the mouse embryo. Dev Biol 44(2):306-12. [PubMed: 1093912]  [MGI Ref ID J:5541]

Zwaan J; Kirkland BM. 1975. Malorientation of mitotic figures in the early lens rudiment of aphakia mouse embryos. Anat Rec 182(3):345-54. [PubMed: 1155804]  [MGI Ref ID J:5562]

Zwaan J; Webster EH Jr. 1984. Histochemical analysis of extracellular matrix material during embryonic mouse lens morphogenesis in an aphakic strain of mice. Dev Biol 104(2):380-9. [PubMed: 6745489]  [MGI Ref ID J:7505]

de Rover M; Lodder JC; Smidt MP; Brussaard AB. 2006. Pitx3 deficiency in mice affects cholinergic modulation of GABAergic synapses in the nucleus accumbens. J Neurophysiol 96(4):2034-41. [PubMed: 16837663]  [MGI Ref ID J:135703]

van den Munckhof P; Gilbert F; Chamberland M; Levesque D; Drouin J. 2006. Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of Parkinson's disease. J Neurochem 96(1):160-70. [PubMed: 16269007]  [MGI Ref ID J:104915]

van den Munckhof P; Luk KC; Ste-Marie L; Montgomery J; Blanchet PJ; Sadikot AF; Drouin J. 2003. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130(11):2535-42. [PubMed: 12702666]  [MGI Ref ID J:82907]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3175.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Embryos

Price (US dollars $)
Frozen Embryo $1600.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $4127.50
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Embryos

Price (US dollars $)
Frozen Embryo $2080.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

General Supply Notes

  • View the complete collection of spontaneous mutants in the Mouse Mutant Resource.

Control Information

  Control
   Heterozygote from the colony
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.5)